IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The insulin-like growth factor II ( IGF2) mRNA binding protein (IMP) p62/IMP2-2, originally isolated from a hepatocellular carcinoma (HCC) patient, induces a steatotic phenotype when overexpressed in mouse livers. Still, p62 transgenic livers do not show liver cell damage but exhibit a pronounced induction of Igf2 and activation of the downstream survival kinase AKT. The aim of this study was to investigate the relation between p62 and IGF2 expression in the human system and to study potential antiapoptotic actions of p62. p62 and IGF2 mRNA levels were assessed by real-time RT-PCR. For knockdown and overexpression experiments, human hepatoma HepG2 and PLC/PRF/5 cells were transfected with siRNA or plasmid DNA. Phosphorylated AKT and ERK1/2 were analyzed by Western blot. Investigations of 32 human HCC tissues showed a strong correlation between p62 and IGF2 expression. Of note, p62 expression was increased markedly in patients with poor outcome. In hepatoma cells overexpression of p62 lowered levels of doxorubicin-induced caspase-3-like activity. Vice versa, knockdown of p62 resulted in increased doxorubicin-induced apoptosis. However, neither PI3K inhibitors nor a neutralizing IGF2 antibody showed any effects. Western blot analysis revealed increased levels of phosphorylated ERK1/2 in hepatoma cells overexpressing p62 and decreased levels in p62 knockdown experiments. When p62-overexpressing cells were treated with ERK1/2 inhibitors, the apoptosis-protecting effect of p62 was completely abrogated. Our data demonstrate that p62 exerts IGF2-independent antiapoptotic action, which is facilitated via phosphorylation of ERK1/2. Furthermore, p62 might serve as a new prognostic marker in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 3×
“Furthermore, p62 might serve as a new prognostic marker in HCC. IMP; hepatocellular carcinoma; apoptosis; ERK; chemoresistance THE INCIDENCE OF HEPATOCELLULAR CARCINOMA (HCC) is rising in most industrialized countries not least because of metabolic risk factors such as obesity and diabetes mellitus and the increasing…”
BackgroundHansen, T. V. O., Hammer, N. A., Nielsen, J., Madsen, M., Dalbaeck, C., Wewer, U. M., Christiansen, J., & Nielsen, F. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.10.4448-4464.2004 · Cited by 251 · cited 1×
“The family member IMP3 has been shown to be implicated in growth promotion, carcinogenesis, angiogenesis, and tumor progression in different tumor types (6, 21, 23, 26).”
BackgroundOverexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype
Tybl, E., Shi, F.-D., Kessler, S. M., Tierling, S., Walter, J., Bohle, R. M., Wieland, S., Zhang, J., Tan, E. M., & Kiemer, A. K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.034 · Cited by 65 · cited 12×
“Primary antibodies used were specific to phospho-ERK1/2, total ERK (New England Biolabs), and p62 (34, 52).”
BackgroundMethodInfluentialSelf-citation
Cited by
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Dai, N., Zhao, L., Wrighting, D., Krämer, D., Majithia, A., Wang, Y., Cracan, V., Borges-Rivera, D., Mootha, V. K., Nahrendorf, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.006 · Cited by 188
Dai, N., Ji, F., Wright, J., Minichiello, L., Sadreyev, R., & Avruch, J. (2017) · eLife · doi:10.7554/elife.27155 · Cited by 103
“…amplified and overexpressed in many cancers and recent reports (Li et al., 2015; Liu et al., 2015; Mu et al., 2015) have pointed to a tumorogenic role in individual cancer types, often with a poor prognosis (Barghash et al., 2015; Bigagli et al., 2016; Davidson et al., 2014; Kessler et al., 2013).”
BackgroundThe Structural Basis for RNA Selectivity by the IMP Family of RNA-Binding Proteins
Biswas, J., Patel, V. L., Bhaskar, V., Chao, J. A., Singer, R. H., & Eliscovich, C. (2019) · Nature Communications · doi:10.1038/s41467-019-12193-7 · Cited by 84
First Small-Molecule Inhibitors Targeting the RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy
Dahlem, C., Abuhaliema, A., Kessler, S. M., Kröhler, T., Zoller, B. G. E., Chanda, S., Wu, Y., Both, S., Müller, F., Lepikhov, K., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00833 · Cited by 70
Self-citation
Metadata
- Authors
- Kessler, S. M., Pokorny, J., Zimmer, V., Laggai, S., Lammert, F., Bohle, R. M., & Kiemer, A. K.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2013-02-15
- Volume
- 304
- Issue
- 4
- Pages
- G328-G336
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2107562345
- Cited by
- 64
- References
- 3
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. https://app.cochat.ai/papers/10.1152/ajpgi.00005.2012
- The paper
- Kessler, S. M., Pokorny, J., Zimmer, V., Laggai, S., Lammert, F., Bohle, R. M., & Kiemer, A. K. (2013). IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00005.2012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.